Results 251 to 260 of about 526,857 (343)

Mortalin and PINK1/Parkin‐Mediated Mitophagy Represent Ovarian Cancer‐Selective Targets for Drug Development

open access: yesAdvanced Science, EarlyView.
Ovarian cancer patients with high levels of mortalin protein in their tumors have worse survival. The investigational drug SHetA2 interferes with mortalin's support of mitochondria. The resulting mitochondrial damage causes a process called mitophagy that contributes to how SHetA2 kills cancer cells. Noncancerous cells repair their mitochondria through
Vishal Chandra   +9 more
wiley   +1 more source

Lung carcinomas in Sprague-Dawley rats after exposure to low doses of radon daughters, fission neutrons, or γ-rays [PDF]

open access: yes, 1989
Chameaud, J.   +5 more
core   +1 more source

Engineering Neutrophil Vesicles for Synergistic Protection against Ischemia/Reperfusion Injury after Lung Transplant

open access: yesAdvanced Science, EarlyView.
Engineered neutrophil‐derived vesicles (SOD2‐Fer‐1@CVs) co‐delivering antioxidant and ferroptosis‐inhibitory agents enable inflammation‐targeted, ROS‐responsive therapy for ischemia–reperfusion injury in lung transplantation. Synergizing with ex vivo lung perfusion, this strategy alleviates oxidative stress and inflammation, restores vascular integrity,
Hao‐Xiang Yuan   +10 more
wiley   +1 more source

CXCR1 Depletion in Ly6C+ cDC2 Alleviates Acute Lung Injury via Modulation of Th17/Treg Balance

open access: yesAdvanced Science, EarlyView.
Pro‐inflammatory Ly6C⁺ cDC2s are identified as key effector cells mediating Cxcr1 signaling, driving the progression of ALI. Ly6C⁺ cDC2s release high levels of Il‐6 and Il‐1β, inducing Th17 differentiation. Cxcr1 deficiency reduces Il‐6 and Il‐1β production from Ly6C⁺ cDC2s through suppressing MEK1/ERK /NF‐κB signaling, thereby shifts naïve T cells ...
Shenghui Li   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy